Apricus Biosciences to Present at the 24th Annual Piper Jaffray Healthcare Conference (AcT)

SAN DIEGO, Nov. 21, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (www.apricusbio.com) announced today that Steve Martin, Interim Chief Executive Officer and Chief Financial Officer, will present at the 24^th Annual Piper Jaffray Healthcare Conference, being held at the New York Palace Hotel in New York City. Mr. Martin's presentation will take place on Tuesday, November 27, 2012 at 4:30 p.m. Eastern Time.

The presentation will be webcast and accessible to the public online at http://www.media-server.com/m/p/m3w45839 or via the Company's website at http://www.apricusbio.com. A replay will be available for 90 days after the presentation.

About Apricus Biosciences, Inc.

Apricus Bio (Nasdaq:APRI) is a pharmaceutical company that develops and markets innovative treatments that help large patient populations across numerous, high-demand therapeutic classes. The Company has three approved products and has developed a strong pipeline of multiple late-stage product candidates. With commercial operations in both the U.S. and Europe (France), Apricus Bio generates revenues and growth from sales of its commercial products and by out-licensing, in certain territories, its pipeline products and NexACT^® technology.

Apricus Bio's growth strategy is to acquire, develop, and commercialize new products through strategic partnerships. The Company currently has commercial partnerships with multiple large pharmaceutical companies including Novartis, Takeda, Abbott Laboratories, Sandoz, Warner Chilcott, and Bracco, and co-promotes multiple products in France.

Apricus Bio is headquartered in San Diego, CA and is publicly traded on the NASDAQ Capital Market under the ticker symbol APRI.

For further information on Apricus Bio, visit http://www.apricusbio.com, and for information on its subsidiary please visit http://www.nexmedusa.com. You can also receive information at http://twitter.com/apricusbio.

CONTACT: Apricus Bio Investor Relations:
David Pitts
Argot Partners
212-600-1902
david@argotpartners.com